However, for the FAS, there was strong evidence, i.e., a highly significant difference between the continue treatment and placebo groups ( n = 34 and 31, respectively) in the estimated mean change in FAS totals between baseline and 6 mo.
← all excerpts
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
1
—
—